Glucose-6-phosphatase dehydrogenase (G6PD) deficiency is the most common enzyme deficiency in humans, affecting 400 million people worldwide and a high prevalence in persons of African, Middle Asian countries. The most common clinical manifestations are neonatal jaundice and acute hemolytic anemia, which is caused by the impairment of erythrocyte’s ability to remove harmful oxidative stress triggered by exogenous agents such as drugs, infection, or fava bean ingestion. Neonatal hyperbilirubinemia caused by glucose-6-phosphate dehydrogenase (G6PD) is strongly associated with mortality and long-term neurodevelopmental impairment. Aim:To determine a level of glucose-6-phosphate dehydrogenase in healthy neonates.The 76.5% of all participants (n=205) was assessed 4.36±1.15 Ug/Hb in normal reference range of G6PD other 23.5% (n=63) was 0.96±0.51 Ug/Hb with G6PD deficiency. In the both sex, 51.5% of male 0.88±0.46Ug/Hb (n=33) and 47.6%of female (n=30) 0.97±0.55Ug/Hb was assessed with G6PDdeficiency. Developing Jaundice period in number of 63 neonates with G6PD deficiency, 85.7% of neonates (n=54)was in 24-72 hours, 4% of neonates (n=3) was in 5-7 days and there is no sign of jaundice in 9% (n=6).Therefore neonates with G6PD deficiency, 53.9% (n=34)contiuned jaundice more than two weeks.G6PD deficiency was determined in male neonates (51.5%) more than female(47.6%). The 76.5% of all participants (n=205) was assessed 4.36±1.15 Ug/Hb in normal reference range of G6PD other 23.5% (n=63) of all participants was 0.96±0.51 Ug/Hb with G6PD deficiency. It shows that G6PD might be one potential risk of neonatal jaundice and hyperbilirubinemia in neonates in Mongolia.

Children under 5 years of age in developing countries are particularly vulnerable to malnutrition. Malnutrition affects 50% of hospitalized children and 25–70% of the critically ill children. Malnutrition interferes with the appropriate response of the body to disease and predisposes to infection and to the onset of multiorgan failure, increasing morbidity and mortality, the mean length of hospital stay, and health costs. Aim: A prospective cohort study of children admitted to the tertiary pediatric ICU between January 2009 and January 2014 was carried out. To assess the malnutrition type, and impact of nutritional status on outcomes like mortality rate, disease, complication in critically ill children.To the study were enrolled 138 children admitted to the pediatric intensive care units of the NationalCenter for Maternal and Childrens Hospital. The study protocol was approved by the Ethics Committee of the MNUMS, and written informed consent was obtained from all study participants. Nutritional status was determined using Waterlow criteria.Total participants were 49.3% (n=68) of male, 50.7% (n=70) female. 138 children with a mean age 4.4 months ±3.6/ Std.Er/, min = 1 month, max = 12 months, mode = 1 month. n=70(50.7%) acute malnutrition, n=58(42%) chronic malnutrition by Waterlow criteria. In malnutrition group was assessed patient with ricket n=36 (26.1%), patient with anemia n=56(58.9%)While malnutrition is a major problem in pediatric intensive care units. Acute malnutrition moreoccurred in the pediatric intensive care.Malnutrition more occurring of intrauterine infection, genetic disorder, hematology disease’s patients.

Jonsh-5 is composed of 5 components including calcite, Cardius crispus, Forsythia suspense, Terminalia Chebula, and Inula helenium. Aim of this study is to examine the effect of traditional drug Jonsh-5 on experimental femur fracture in rats. Jonsh-5 was given to rats for 28 days. Calcium D3-Nycomed (2.5 g/kg) was used for comparison. 2, 14, and 28 days after fracture, serum levels of alkaline phosphatase were determined and fracture healing processes were evaluated by X-ray. Serum level of alkaline phosphatase was 197 u/l before fracture. After 7 days of fracture, alkaline phosphatase level was significantly increased by Jonsh-5 (728 u/l) and there were no statistical differences observed in rats with no treatment (control) and Calcium D3-Nycomed-treated animals. Similar patterns were observed 14 and 21 days after fracture. X-ray images showed that healing process of the bone was significantly increased by Jonsh-5 compare to control and Calcium D3-Nycomed treatment. Jonsh-5 may promote bone healing in rat model of fracture.